Bonaventure Equity
1250 Elizabeth Ave. #13, West Palm Beach, FL, 33410, United States
Overview
Bonaventure Equity operates as a cannabis venture capital firm, committed to funding the next generation of innovative cannabis companies delivering economic, societal, cultural and healthcare benefits through leading technologies, services and science.
- Total investments
- 2
- Lead investments
- 1
- Investments · 12mo
- 0
- Active investors
- 2
Sector focus
- Health Care
- Innovation Management
- Venture Capital
Investment portfolio
- Nalu Bio
Participated · Series A · Feb 2023
Nalu Bio is a biotech company creating chemistry-based cannabinoids for the consumer and pharmaceutical markets. Its platform generates molecularly identical versions of naturally occurring cannabinoids (CBD, THCV, CBN, CBC, CBG) that are sustainable and free from contaminants found in hemp-extracted cannabinoids. The company intends to use recent funding to accelerate growth and scale production of cannabinoids for consumer products and therapeutics. Nalu Bio was founded in 2019 and is led by CEO Caitlyn Krebs. It is headquartered in San Francisco, CA. The company's technology targets both consumer product and therapeutic applications. Nalu Bio develops next-generation cannabinoid ingredients via a chemistry-based proprietary synthesis platform that produces ultra-pure, consistently performing cannabinoids without contamination risks associated with hemp extraction. The platform is scalable and designed to meet anticipated market expansion, supplying global retail and pharmaceutical markets. The company emphasizes research- and evidence-based cannabinoids and operates with a team of chemists and scientists focused on transparency and quality. Nalu Bio positions its products as free from THC, heavy metals, and pesticides, aiming for wide accessibility and high quality. Leadership highlights a commitment to rigorous standards when partnering with investors and scaling operations.
- LeafWorks
Led · Series A · Feb 2020
LeafWorks Inc. is a female-founded genetics company based in Sebastopol, Calif., specializing in plant identification, research, and development for the cannabis, hemp, and herbal industries. Its core offering is DNA-based tests and services that confirm verifiable ingredient authenticity and combat widespread mislabeling in the marketplace. LeafWorks is the exclusive DNA testing company partner of Canndor Herbarium, which houses genetic material that supports its scientific efforts. The company says it will use new capital to strategically scale its business and solidify its role within B2B and B2C cannabis and herbal markets. LeafWorks aims to become the standard third-party verification provider, enabling clients to provide transparency about crop and product identity across supply chains. Leadership includes co-founders CEO Eleanor Kuntz, PhD, and CSO Kerin Law, PhD, and the company emphasizes rigorous scientific standards and supply-chain transparency.